brafv600e-mutant

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colore

This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination…

6 hours ago